Login to Your Account



After Adding $25M, Novacea To Launch DN-101 Phase III

By Karen Pihl-Carey


Thursday, January 5, 2006
Closing the second tranche of a Series C financing begun two years ago, Novacea Inc. raised more than $25 million - money it will use to launch a Phase III trial with DN-101 to treat advanced prostate cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription